Journal article icon

Journal article

PCSK9 inhibition: ready for prime time in CKD?

Abstract:
Lowering LDL cholesterol reduces the risk of atherosclerotic vascular disease in a wide range of patients with chronic kidney disease, with no evidence of a threshold below which further reductions no longer reduce risk. Statins safely lower LDL cholesterol, but novel inhibitors of proprotein convertase subtilisin kexin 9 (PCSK9) provide additional reductions which may reduce atherosclerotic vascular disease yet further in this high risk population.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.kint.2018.01.030

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Nuffield Dept of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
ORCID:
0000-0002-1179-0023
Publisher:
Elsevier
Journal:
Kidney International More from this journal
Publication date:
2018-05-21
Acceptance date:
2018-01-25
DOI:
EISSN:
1523-1755
ISSN:
0085-2538
Pmid:
29792269
Language:
English
Keywords:
Pubs id:
pubs:853916
UUID:
uuid:0be6a7ee-6077-4d8a-b023-71466ca1fcfb
Local pid:
pubs:853916
Source identifiers:
853916
Deposit date:
2019-02-27

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP